Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- benzoyl peroxide / clindamycin / niacinamide / tretinoin topical
- porfimer
Interactions between your drugs
tretinoin topical benzoyl peroxide topical
Applies to: benzoyl peroxide / clindamycin / niacinamide / tretinoin topical, benzoyl peroxide / clindamycin / niacinamide / tretinoin topical
GENERALLY AVOID: Concomitant use of retinoids and keratolytic or astringent topicals may result in excessive irritation and/or drying.
MANAGEMENT: Depending on circumstances (e.g., areas of application), concomitant use should preferably be avoided, and a rest period considered in between use of these products.
References (2)
- (2001) "Product Information. Retin-A (tretinoin)." Ortho McNeil Pharmaceutical
- (2001) "Product Information. Tazorac (tazarotene topical)." Allergan Inc
tretinoin topical porfimer
Applies to: benzoyl peroxide / clindamycin / niacinamide / tretinoin topical, porfimer
GENERALLY AVOID: Patients exposed to photosensitizing agents at the same time as or in the 30 to 90 days following treatment with porfimer may be at an increased risk of a photosensitivity reaction (e.g., erythema, swelling, pruritus, burning sensations, feeling hot, and/or blisters). These agents have each been individually associated with photosensitivity reactions and may have additive effects if used together. Medicinal products with known phototoxic or photoallergic potential include, but are not limited to, hypericin-containing products (e.g., St. John's Wort), griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, quinolones, and tetracyclines. Photosensitivity with porfimer is due to residual drug being present in the skin. Porfimer is cleared from a variety of tissues over 40 to 72 hours after treatment, but organs of the reticuloendothelial system (e.g., liver, spleen), skin and the tumor itself retain the drug for a longer period. Patients treated with porfimer will be photosensitive for at least 30 days and possibly up to 90 days or more for patients with hepatic or severe renal dysfunction. In clinical studies of porfimer, photosensitivity reactions occurred in approximately 20% of cancer patients and 69% of high-grade dysplasia in Barrett's esophagus patients.
MANAGEMENT: Use of photosensitizing agents should be avoided for at least 30 days and maybe up to 90 days or longer after porfimer treatment depending on the patient's hepatic function, renal function, and/or ability to tolerate exposure to sunlight. Following treatment with porfimer, patients should follow measures outlined in the product labeling for light and sun exposure. It is important to counsel patients to expose their skin to ambient indoor light as it is not only safe but will help eliminate porfimer through the skin by a process called "photobleaching." Before exposing skin or eyes to direct sunlight or bright indoor light (e.g., examination lamps, dental lamps, operating room lamps, floodlights, halogen lamps, unshaded light bulbs at close proximity, etc.), patients should test for residual photosensitivity as described in porfimer's product labeling.
References (5)
- Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B (2020) "The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature." J Eur Acad Dermatol Venereol, 34, p. 589-600
- Blakely KM, Drucker AM, Rosen CF (2019) "Drug-induced photosensitivity—an update: Culprit drugs, prevention and management." Drug Saf, 42, p. 827-47
- (2023) "Product Information. Photofrin (porfimer)." Pinnacle Biologicals, Inc.
- Concordia Laboratories Inc. (2023) Photofrin sterile porfimer sodium for injection for intravenous use antineoplastic photosensitizing agent. https://pdf.hres.ca/dpd_pm/00028148.PDF
- Pinnacle Biologics B.V. (2023) Annex I summary of product characteristics https://www.ema.europa.eu/en/documents/product-information/photobarr-epar-product-information_en.pdf
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Vibramycin
Vibramycin is used for acne, actinomycosis, amebiasis, anthrax, anthrax prophylaxis, bacterial ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Minocycline topical
Minocycline topical is used for acne, periodontitis, rosacea
Clindamycin topical
Clindamycin topical is used for acne, bacterial vaginosis, perioral dermatitis
Accutane
Accutane (isotretinoin) is a form of vitamin A and is used to treat severe nodular acne. Includes ...
Tretinoin topical
Tretinoin is used to treat acne (pimples) and sun damage as an anti-aging to help reduce the ...
Minocycline
Minocycline is used to treat infections, such as urinary tract infections, acne and chlamydia ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.